Typical experimental endpoints include measures of collagen and extracellular matrix protein expression, cell migration rates, cytoskeletal organization, and transcriptional changes in genes related to tissue structure and repair, depending on the model
Beyond shedding pounds, these medications positively impact numerous weight-related conditions: Cardiovascular disease risk reduction of approximately 20% (MACE) with GLP1s Improvements in sleep apnea (reduction of 6 fewer events per hour) Better management of non-alcoholic fatty liver disease Significant improvements in blood pressure, cholesterol, and blood sugar Reduced risk for cardiovascular and all-cause mortality Delayed progression to diabetes The weight loss threshold for meaningful health improvements typically starts at 5-10% of body weight
Prior to Crenessitys approval, patients and their providers managed symptoms with glucocorticoids, which can help correct enzyme imbalances but can come with side effects such as osteoporosis and diabetes
M.ShawgoT.et al (2020)
Taken together, our data indicate that ART and its derivatives exhibit significant but delayed effects on glutathione metabolism
